Kaleido Beneish M Score

KLDO -  USA Stock  

USD 5.67  0.52  8.40%

This module uses fundamental data of Kaleido Biosciences to approximate the value of its Beneish M Score. Kaleido Biosciences M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Please see Kaleido Biosciences Piotroski F Score and Kaleido Biosciences Altman Z Score analysis.

Search Beneish M Score 

 
Refresh
Kaleido Biosciences Total Debt is quite stable at the moment as compared to the past year. The company's current value of Total Debt is estimated at 21.34 Million. Debt Non Current is expected to rise to about 19.6 M this year, although the value of Debt Current will most likely fall to about 2.4 M. Kaleido Biosciences Book Value per Share is quite stable at the moment as compared to the past year. The company's current value of Book Value per Share is estimated at 0.66. Current Ratio is expected to rise to 4.08 this year, although the value of Earnings per Basic Share will most likely fall to (2.63) .
At this time, it appears that Kaleido Biosciences is an unlikely manipulator. The earnings manipulation may begin if Kaleido Biosciences' top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Kaleido Biosciences executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Kaleido Biosciences' earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-4.11
Beneish M Score - Unlikely Manipulator
Elasticity of Receivables
1.0
Asset Quality
N/A
Expense Coverage
0.96
Gross Margin Strengs
0.99
Accruals Factor
0.96
Depreciation Resistance
1.04
Net Sales Growth
0.99
Financial Leverage Condition
0.86

Kaleido Biosciences Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Kaleido Biosciences' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Revenues872.4 K877.5 K
Slightly Down
Decreasing
Slightly volatile
Selling General and Administrative Expense22.8 M23.9 M
Sufficiently Down
Increasing
Slightly volatile
Depreciation Amortization and Accretion1.6 M1.8 M
Fairly Down
Increasing
Slightly volatile
Total Assets68.5 M59.3 M
Fairly Up
Increasing
Slightly volatile
Property Plant and Equipment Net7.6 M8.5 M
Moderately Down
Increasing
Slightly volatile
Trade and Non Trade Receivables40.3 K40.5 K
Slightly Down
Decreasing
Slightly volatile
Total Liabilities38.2 M38.8 M
Fairly Down
Increasing
Slightly volatile
Current Assets58.5 M48.7 M
Fairly Up
Increasing
Slightly volatile
Assets Non Current10.1 M10.6 M
Notably Down
Increasing
Slightly volatile
Current Liabilities14.9 M16.7 M
Moderately Down
Increasing
Slightly volatile
Liabilities Non Current23.3 M22.2 M
Sufficiently Up
Increasing
Slightly volatile
Total Debt21.3 M21 M
Fairly Up
Increasing
Slightly volatile
Debt Current2.4 M2.4 M
Slightly Down
Decreasing
Slightly volatile
Debt Non Current19.6 M18.4 M
Notably Up
Increasing
Slightly volatile
Gross Margin0.890.9
Fairly Down
Decreasing
Slightly volatile

Kaleido Biosciences Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Kaleido Biosciences' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Kaleido Biosciences in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Kaleido Biosciences' degree of accounting gimmicks and manipulations.

About Kaleido Biosciences Beneish M Score

M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.

Depreciation Amortization and Accretion

1.57 MillionShare
Kaleido Biosciences Depreciation Amortization and Accretion is quite stable at the moment as compared to the past year. The company's current value of Depreciation Amortization and Accretion is estimated at 1.57 Million

About Kaleido Biosciences Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Kaleido Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kaleido Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kaleido Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Kaleido Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 82 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Kaleido Biosciences without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Instant Ratings Now

   

Instant Ratings

Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Kaleido Biosciences using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Kaleido Biosciences Piotroski F Score and Kaleido Biosciences Altman Z Score analysis. Note that the Kaleido Biosciences information on this page should be used as a complementary analysis to other Kaleido Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Complementary Tools for Kaleido Stock analysis

When running Kaleido Biosciences price analysis, check to measure Kaleido Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kaleido Biosciences is operating at the current time. Most of Kaleido Biosciences' value examination focuses on studying past and present price action to predict the probability of Kaleido Biosciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kaleido Biosciences' price. Additionally, you may evaluate how the addition of Kaleido Biosciences to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
The market value of Kaleido Biosciences is measured differently than its book value, which is the value of Kaleido that is recorded on the company's balance sheet. Investors also form their own opinion of Kaleido Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Kaleido Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kaleido Biosciences' market value can be influenced by many factors that don't directly affect Kaleido Biosciences underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kaleido Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Kaleido Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kaleido Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.